NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent. According ...

James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

NATICK, Mass., January 21, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including ...

Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular GLP-1 medicines like Novo Nordisk's Wegovy, could improve muscle mass and overall body ...

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program ...